Startup BioNanoTech has developed a patented platform technology for purifying proteins/antibodies across size ranges.
In particular, the company has developed a new class of Immobilization Metal Affinity Chromatography (IMAC) nanoresins.
“We are building something new at a new scale, and something that can do chemistry and physics on a scale that is more closely to what the target molecules are,” said John Harrold, chief scientific officer at BioNanoTech.
You can read the entire article here in Drug Discovery & Development: https://www.drugdiscoverytrends.com/the-startup-bionanotech-aims-to-usher-in-new-frontier-in-protein-purification/
Do you have questions? Let us know how we can help! Contact us or subscribe to our newsletter and we will be in touch as soon as possible.
Comments